Drugs / AAA817
AAA817
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07054346 | Jul 2025 → Apr 2027 expected | prostate carcinoma | Thomas Hope | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07150715 | Dec 2025 → Oct 2030 expected | prostate adenocarcinoma | Jonsson Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06780670 | Feb 2025 → Jun 2028 expected | prostate cancer | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06855277 | Jul 2025 → Sep 2028 expected | prostate cancer | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAA817 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06855277 ↗ |
| Known as | 225Ac-PSMA-617 | “Five participants will receive a single dose of 225Ac-PSMA-617 radioligand therapy IV, five participants will receive a single dose of 225Ac-PSMA-617 IA, and five participants...” NCT07054346 ↗ |
| Known as | Actinium Ac 225 Vipivotide Tetraxetan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07150715 ↗ |
| Action | Deplete | “225Ac-PSMA-617 or 177Lu-PSMA-617 builds up in these cells and gives off either alpha or beta radiation that may kill them.” NCT07150715 ↗ |
| Modality | Other / unclassified | “This treatment is also called a radioligand therapy.” NCT06855277 ↗ |
| Route | Intravenous | “given intravenously” NCT06855277 ↗ |